OLDSMAR

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022

Retrieved on: 
Tuesday, February 28, 2023
NYSE American, CCEL, Cryo-Cell International, Cryptocurrency

Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021.

Key Points: 
  • Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021.
  • The Company reported net income of $2.8 million in fiscal 2022 or $0.33 per basic and diluted share, compared to net income of $2.1 million in fiscal 2021 or $0.26 per basic and $0.25 per diluted shares.
  • Net income for the fiscal year ended November 30, 2022 was due to a 5% increase in revenue, a 2% decrease in cost of sales and a 7% increase in selling, general and administrative expenses compared to the prior fiscal year.
  • Also included in net income for the twelve months ended November 30, 2021 was a public bank inventory impairment charge of $1.2 million.

Sunbelt Expands Headquarters

Retrieved on: 
Wednesday, February 8, 2023
Sun Belt, Health, Education, Season, Feedback, School, Human, Interior design

In the past year, Sunbelt has grown from one office to three, and they have doubled their internal workforce for a total of 250 colleagues.

Key Points: 
  • In the past year, Sunbelt has grown from one office to three, and they have doubled their internal workforce for a total of 250 colleagues.
  • The company is projected to reach 350 colleagues by 2024, bringing new jobs to the Tampa area.
  • This has increased their capacity to serve schools and healthcare systems with over 2,500 healthcare and education professionals across the U.S.
    “At Sunbelt, everything we do starts with a premium mindset.
  • We strive for the best in all we do for our colleagues, clients, and healthcare and education professionals,” said Ken Kistner, vice president of healthcare at Sunbelt.

Opswright Revolutionizes Critical Infrastructure Security

Retrieved on: 
Monday, January 16, 2023
Red team, Chronic cerebrospinal venous insufficiency controversy, Data breach, World Economic Forum, Organization, United States national laboratories, Research, IBM, Food, Medical device, Risk management, Colonial

MELBOURNE, Fla., Jan. 16, 2023 /PRNewswire-PRWeb/ -- Opswright, a new cybersecurity company based in Melbourne, FL, announces the launch of its Impact Platform, a revolutionary security engineering design tool for critical infrastructure.

Key Points: 
  • Opswright, a new cybersecurity company based in Melbourne, FL, announces the launch of its Impact Platform, a revolutionary security engineering design tool for critical infrastructure.
  • MELBOURNE, Fla., Jan. 16, 2023 /PRNewswire-PRWeb/ -- Opswright, a new cybersecurity company based in Melbourne, FL, announces the launch of its Impact Platform, a revolutionary security engineering design tool for critical infrastructure.
  • Additionally, they identified the top risk is energy scarcity, a condition that can be directly linked to critical infrastructure weaknesses.
  • Opswright founder Tony Turner, an industry veteran with over 25 years of experience in cybersecurity, has spent the last decade helping critical infrastructure organizations focus on the risks that matter.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2022 Financial Results

Retrieved on: 
Friday, October 14, 2022
Drug Quality and Security Act, Sale, FACT, Accreditation, Person, Parent, CCEL, Patient, Hospital, Income, Licensure, Securities Act of 1933, Baptist Hospital, Partnership, NYSE American, AABB, Company, Cryo-Cell International, IP, Securities Exchange Act of 1934, GLOBE, Terminology, FDA, COVID-19, Ownership, Duke University, Risk, Pharmaceutical industry

OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022.

Key Points: 
  • OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022.
  • Consolidated revenues for the third quarter of fiscal 2022 were $7.7 million compared to $7.5 million for the third quarter of fiscal 2021.
  • Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Cord Blood Banking Leader Cryo-Cell Announces Special Cash Dividend

Retrieved on: 
Monday, August 22, 2022
Partnership, Cryo-Cell International, COVID-19, Securities Exchange Act of 1934, Securities Act of 1933, Accreditation, Ownership, Risk, Person, Board, Parent, Licensure, Duke University, Hospital, FACT, GLOBE, Nasdaq, Board of directors, AABB, Company, FDA, IP, Terminology, Baptist Hospital, Patient, Pharmaceutical industry, Director

Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.

Key Points: 
  • Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Cryo-Cells public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as CedarsSinai Hospital in Los Angeles and Baptist Hospital in Miami.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

Cord Blood Banking Leader Cryo-Cell Announces Transfer to the NYSE American Stock Exchange

Retrieved on: 
Wednesday, August 17, 2022
FDA, Securities Act of 1933, NYSE, GLOBE, Technology, Securities Exchange Act of 1934, IP, Terminology, Hospital, Board, Hope, Cryo-Cell International, Compliance, Nasdaq, Patient, COVID-19, Company, Licensure, Parent, Partnership, Risk, Board of directors, Ownership, Accreditation, NYSE American, AABB, Duke University, FACT, Baptist Hospital, Person, Pharmaceutical industry

After careful evaluation, we concluded that the NYSE American stock exchange is a better fit for Cryo-Cell now and hope that it will result in a more liquid trading market for our shareholders.

Key Points: 
  • After careful evaluation, we concluded that the NYSE American stock exchange is a better fit for Cryo-Cell now and hope that it will result in a more liquid trading market for our shareholders.
  • In addition, Cryo-Cell will be immediately in compliance with the rules of the NYSE American with regard to the current structure of our Board of Directors.
  • Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2022 Financial Results

Retrieved on: 
Monday, July 11, 2022
Nasdaq, Partnership, AABB, Cryo-Cell International, Person, FACT, FDA, COVID-19, Terminology, Risk, Securities Exchange Act of 1934, Parent, Baptist Hospital, Company, Ownership, IP, Licensure, Income, Accreditation, Securities Act of 1933, Sale, GLOBE, Patient, Duke University, Hospital, Pharmaceutical industry

OLDSMAR, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2022.

Key Points: 
  • OLDSMAR, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2022.
  • Consolidated revenues for the second quarter of fiscal 2022 were $7.63 million compared to $7.21 million for the second quarter of fiscal 2021, a 6% increase.
  • The revenues for the second quarter of fiscal 2022 consisted of $7.48 million in processing and storage fee revenue, $117,000 in public banking revenue and $36,000 in product revenue compared to $7.16 million in processing and storage fee revenue and $46,000 in public banking revenue for the second quarter of fiscal 2021.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Sunbelt Recognized as Business of Quarter by the City of Oldsmar

Retrieved on: 
Tuesday, May 10, 2022
Business, Employment, Sun Belt, Â, GLOBE, School, Commerce, City, Friends, Life, Goal, Work, Management

That passion has now earned the staffing company recognition from the City of Oldsmar as the Business of the Quarter, lauding the organization for the work it does in enhancing life, work, and play in the small Florida community.

Key Points: 
  • That passion has now earned the staffing company recognition from the City of Oldsmar as the Business of the Quarter, lauding the organization for the work it does in enhancing life, work, and play in the small Florida community.
  • Oldsmar Vice-Mayor Jarrod Buchman presented the Business of the Quarter award to Sunbelt during a city council meeting on April 19.
  • On behalf of the entire Sunbelt team, Id like to thank the City of Oldsmar for recognizing us with the Business of the Quarter award, said Ken Kistner, Vice President of Sunbelt.
  • Sunbelt has been awarded the Business of Quarter in 2015 and 2022 by the City of Oldsmar as well as the Large Business of the Year in 2013 and 2019 by the Upper Tampa Bay Chamber of Commerce.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, April 13, 2022
Board, COVID-19, Licensure, CCEL, AABB, Hospital, GLOBE, Sale, Risk, Terminology, Drug Quality and Security Act, Patient, OTC, Duke University, Securities Exchange Act of 1934, Ownership, Person, Baptist Hospital, Company, Cryo-Cell International, Parent, Income, IP, Partnership, FDA, Acquisition, Securities Act of 1933, Accreditation, FACT, Pharmaceutical industry

OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2022.

Key Points: 
  • OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2022.
  • The revenues for the first quarter of fiscal 2022 were $7.26 million compared to $6.86 million for the first quarter of fiscal 2021.
  • Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Cord Blood Banking Leader Cryo-Cell Announces Extravault Biorepository Service

Retrieved on: 
Wednesday, March 16, 2022
Research, Solution, GLOBE, Patient, Cryo-Cell International, Partnership, AABB, Hospital, Ownership, Research Triangle, FDA, Nasdaq, Accreditation, COVID-19, Duke University, Licensure, Person, Parent, IP, Company, Baptist Hospital, FACT, Securities Exchange Act of 1934, Drug Quality and Security Act, Securities Act of 1933, Terminology, Fine chemical, Pharmaceutical industry

We anticipate this facility will expand Cryo-Cells cryopreservation and cold storage business by introducing a new service, ExtraVault ( www.extravault.com ).

Key Points: 
  • We anticipate this facility will expand Cryo-Cells cryopreservation and cold storage business by introducing a new service, ExtraVault ( www.extravault.com ).
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.
  • Cryo-Cells public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as CedarsSinai Hospital in Los Angeles and Baptist Hospital in Miami.
  • Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.